Related Experiment Videos
[Clinical studies on cefminox in the field of pediatrics]
Insights
Cefminox (CMNX), a new cephamycin antibiotic, showed excellent results in treating pediatric bacterial infections, including tonsillitis and UTIs. While one mixed infection case was unresponsive, CMNX demonstrated effectiveness and a favorable safety profile in most pediatric patients.
Area of Science:
- Infectious Diseases
- Pediatrics
- Pharmacology
Background:
- Bacterial infections pose a significant health challenge in pediatric populations.
- The cephamycin group of antibiotics offers a broad spectrum of activity against various pathogens.
- Novel antibiotic development is crucial for combating resistant bacterial strains.
Purpose of the Study:
- To evaluate the clinical efficacy and safety of cefminox (CMNX) in treating pediatric bacterial infections.
- To assess the pharmacokinetic profile of CMNX in children.
- To determine the effectiveness of CMNX against specific bacterial pathogens commonly found in pediatric infections.
Main Methods:
- Clinical trial involving pediatric patients with bacterial infections (lacunar tonsillitis, urinary tract infections).
- Intravenous administration of cefminox (CMNX) at daily doses of 58.1–122.7 mg/kg in 3 divided doses.
- Monitoring of clinical response, side effects, and blood levels; assessment of urinary recovery rate.
Main Results:
- Cefminox (CMNX) demonstrated excellent efficacy in 4 out of 5 assessable cases of pediatric bacterial infections.
- One case of mixed infection (E. coli and E. faecalis) showed ineffectiveness.
- Reported side effects included rashes in one case and slight GOT elevation in another; T 1/2 was 1.27 hours with a 6-hour urinary recovery rate of 78.6%.
Conclusions:
- Cefminox (CMNX) is a promising new cephamycin antibiotic for treating pediatric bacterial infections.
- The drug exhibits a favorable efficacy and safety profile in the pediatric population for susceptible infections.
- Further investigation may be warranted for mixed infections involving E. faecalis.
Abstract:
A new antibiotic of cephamycin group, cefminox (CMNX, MT-141), was evaluated clinically in the treatment of bacterial infections in children. The following results were obtained. One case of lacunar tonsillitis (due to H. influenzae) and 5 cases of urinary tract infections (due to E. coli in 2 cases, mixed infection due to E. coli and E. faecalis in 1 case, due to K. pneumoniae in 1 case and causative organism was unknown in 1 case) were treated intravenously with CMNX at daily doses ranging from 58.1 to 122.7 mg/kg in 3 divided doses. One case in which the treatment was discontinued after 1 day because of rashes was excluded from assessment of efficacy. Among the remaining 5 cases, CMNX was found ineffective for 1 case of mixed infection due to E. coli and E. faecalis. However, in all of the other 4 cases excellent results were obtained. As side effects, rashes developed in 1 case and slight elevation in GOT in 1 case out of 6 cases. Blood levels following bolus intravenous injection of 20 mg/kg of CMNX were 68, 45, 27, 10.2 and 3.1 micrograms/ml at 1/2, 1, 2, 4 and 6 hours, respectively, with T 1/2 of 1.27 hours. The urinary recovery rate within the first 6 hours was 78.6%.